CytomX Therapeutics (CTMX) Total Current Liabilities (2014 - 2026)

CytomX Therapeutics has reported Total Current Liabilities for 13 years, with the latest figure at $34.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 32.23% year-over-year to $34.0 million; the trailing twelve-month figure through Mar 2026 stood at $34.0 million (down 32.23% YoY), and the FY2025 full-year result was $46.6 million, down 45.65% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $34.0 million, down from $46.6 million in the prior quarter.
• The five-year high for Total Current Liabilities was $155.9 million in Q4 2023, with the low at $34.0 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $103.4 million across 5 years, with a median of $119.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 95.98% — and 2025, when it slumped 72.54%.
• CytomX Therapeutics' Total Current Liabilities stood at $152.6 million in 2022, then grew by 2.17% to $155.9 million in 2023, then slumped by 44.99% to $85.8 million in 2024, then sank by 45.65% to $46.6 million in 2025, then retreated by 27.01% to $34.0 million in 2026.
• The last three Total Current Liabilities figures came in at $34.0 million (Q1 2026), $46.6 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.